Currently, we do not have any Epilepsy or Seizure trials open to enrollment. Trials are added on an ongoing basis. Please check back at a later date.
Title: An open-label, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam (up to 200mg/day) used as adjunctive treatment at a flexible dose up to a maximum of 200mg/day in subjects in subjects suffering from partial onset seizures Principal Investigator: Joel Oster, MD Sponsor: UCB, Inc. Summary: The purpose of this study is to evaluate the long-term safety and efficacy of brivaracetam as an adjunctive treatment (maximum dose 200 mg/day) for partial onset seizures. Title: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Principal Investigator: Joel Oster, MD Sponsor: UCB, Inc. Summary: This is an 18-week, double-blind, randomized, historical control, multicenter study with conversion to monotherapy in subjects with partial onset seizures sponsored by Sunovion Pharmaceuticals, Inc. The primary objective of this study is to evaluate the efficacy of eslicarbazepine acetate (Stadesa™) monotherapy in subjects with partial epilepsy not well controlled by current AEDs. Patients who enroll into this trial will have the option of tapering off study drug at the completion of this study or rolling over into the open label extension study: Long Term Eslicarbazepine Acetate Extension Study Title: A phase 3, Randomized, Double-Blind, Parallel, Placebo Controlled, Multicenter Study, with Optional Open Label Continuation, of the Efficacy and Safety of Vanquix Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory, Patients with Epilepsy who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures Principal Investigator: Joel Oster, MD Sponsor:Pfizer Summary: The primary objectives of this study are: 1) to evaluate the efficacy of Vanquix™ for the management of selected, refractory, patients with epilepsy who require intermittent medical intervention provided by caregivers to control episodes of acute repetitive seizures (ARS), and 2) to evaluate the safety of Vanquix™ when administered by caregivers who are not health care professionals, and who are not under the direct supervision of a healthcare professional at the time of administration. Title: An Open-Label, Multinational, Multi-center, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam, Used at a Flexible Dose up to a Maximum of 150 mg/day, in Subjects Aged 16 Years or Older Suffering From Epilepsy Principal Investigator: Joel Oster, MD Sponsor: UCB, Inc. Summary: This is a phase III, therapeutic confirmatory long-term follow-up, multinational, multi-center, non-comparative, open-label and single arm trial sponsored by UCB. The primary objective is to evaluate the long-term safety and tolerability of brivaracetam at individualized doses with a maximum of 150 mg/day in subjects suffering from epilepsy.
RESEARCH IN NEUROLOGY
The American Heart Association/American Stroke Association's Get With The Guidelines program has again awarded Lahey Clinic’s stroke service the Stroke Gold Performance Achievement Award.